Trinity Biotech plc (TRIB)
| Previous close | 1.7000 |
| Open | 1.6800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.6500 - 1.7699 |
| 52-week range | 1.6500 - 5.5000 |
| Volume | |
| Avg. volume | 17,703 |
| Market cap | 15.618M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.8000 |
| Earnings date | 04 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 June 2015 |
| 1y target est | N/A |
GlobeNewswireTrinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM s
Insider MonkeyTrinity Biotech plc (NASDAQ:TRIB) Q4 2023 Earnings Call Transcript
Trinity Biotech plc (NASDAQ:TRIB) Q4 2023 Earnings Call Transcript April 4, 202 Trinity Biotech plc isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings! Welcome to the Trinity Biotech’s Fourth Quarter and Full Year 2023 Earnings Conference Call. At this […]
- GuruFocus.com
Trinity Biotech PLC (TRIB) Q4 2023 Earnings Call Transcript Highlights: A Glimpse into ...
Trinity Biotech reveals Q4 results and strategic initiatives amidst a challenging fiscal year, setting the stage for a transformative 2024.
